Rick Altinger, CEO, Glooko
Rick Altinger has spent 20 years in the technology industry, concentrating on healthcare information technologies for the last 15 years. At Intuit, he launched the healthcare division’s provider services and drove the effort that resulted in Intuit acquiring Medfusion in May 2010. Medfusion, now the core of Intuit Health, is the leading supplier of patient-provider communication and patient portal services that improve healthcare by delivering groundbreaking clinical, administrative and financial services. Prior to joining Intuit, Mr. Altinger was an Executive Vice President at AdvancedMD, a Practice Mgt/Electronic Health Record company that he helped through a turnaround. Mr. Altinger was also an early employee at Healtheon/WebMD where he served as Vice President of Business Development setting product strategy and driving major acquisitions including WebMD, Envoy, Medical Manger, Kinetra and MedE America. Prior to his business development role at Healtheon, Mr. Altinger played numerous roles including leading product management, account management and systems integration.
Mark Carlson, Vice President Global Clinical Affairs and Chief Medical Officer
Mark Carlson is Vice President Global Clinical Affairs and Chief Medical officer, St. Jude Medical. In this capacity, Dr. Carlson leads a global clinical affairs organization for St. Jude Medical across all divisions. Dr. Carlson joined St. Jude Medical in November 2006, serving as Chief Medical Officer and Senior Vice President, Research and Clinical Affairs, in the St. Jude Medical Implantable Electronic Systems Division until September, 2013.
Dr. Carlson received his M.D. from the University of Kansas, and a Masters degree in public policy from Duke University and a B.S from Kansas State University. He trained in internal medicine at University Hospitals of Cleveland and Case Western Reserve University and in cardiology and cardiac electrophysiology at the Massachusetts General Hospital and Harvard University. He joined the faculty of Case Western Reserve University in 1988 and remains on faculty as adjunct professor of medicine. His research on arrhythmias and neural control has resulted in over 150 publications. As a Robert Wood Johnson Fellow on Senator Orrin Hatch’s Senate Judiciary Committee, Dr. Carlson worked on the Medicare Prescription Drug, Improvement and Modernization Act and the Cord Blood Stem Cell Act. Thereafter, he returned to Case as associate vice president, government relations. Dr. Carlson served on the FDA’s Devices Dispute Resolution Panel, the NCDR ICD registry steering committee, and chaired the HRS Health Policy Committee, the ACC Electrophysiology Committee, the HRS/FDA Policy Conference on Device Performance, and the HRS task force on device performance policies and guidelines and the Medicare Evidence Development & Coverage Advisory Committee.
Michael Farrell CEO, ResMed
Michael J. Farrell became chief executive officer in March 2013. Mr. Farrell has served as the Company’s president – Americas since May 2011. He was previously senior vice president, strategic business unit – sleep from July 2007 to May 2011, and before that role he was vice president, marketing for the Americas from June 2005 through July 2007, and vice president, business development. Before joining the Company in September 2000, Mr. Farrell worked in management consulting and biotechnology, as well as in chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company, and BHP Billiton. Mr. Farrell sits on the board of directors of the American Association for Homecare, the Museum of Photographic Arts, San Diego, and the New Children’s Museum, San Diego. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management. In addition to his appointment as chief executive officer, Mr. Farrell was appointed to serve as a director on the Board effective as of March 1, 2013.
David Gollaher, President and Chief Executive Officer CHI-California Healthcare Institute (Moderator)
David L. Gollaher, Ph.D., co-founded CHI in 1993. Previously, he was a senior executive at Scripps Clinic and Research Foundation. Earlier in his career, he served on the faculties of Harvard University, University of California, San Diego, the Graduate School of Public Health at SDSU, and the Overseas School of Rome. He is an award-winning historian of science and medicine, and has written three books and numerous articles in the fields of health policy, the economics of biomedical research and development, bioethics and the history of medicine.
The story behind the "bionic eye"
MassDevice publisher sits down with Dr. Robert Greenberg, CEO/Founder of Second Sight for a discussion on the 20-year journey behind the company's revolutionary Argus II "Bionic Eye," recently names the invention of the year by Science Magazine.
Dr. Robert Greenberg CEO/Founder, Second Sight
Dr. Greenberg has worked in the field of retinal prosthetics for over twenty years. From 1991 to 1997, Dr. Greenberg conducted pre-clinical and clinical trials demonstrating the feasibility of retinal electrical stimulation to elicit visual perceptions. From 1997 to 1998, he served as a medical officer and lead reviewer for IDEs and 510(k)s at the Office of Device Evaluation at the U.S. Food and Drug Administration in the Neurological Devices Division. In 1998, he received his medical and doctorate degrees from The Johns Hopkins School of Medicine. Dr. Greenberg has been CEO since the founding of the company. Dr. Greenberg currently sits on the board of directors of the Southern California Biomedical Council, the Los Feliz Arts Charter and one of Alfred Mann's foundations.
Brian Johnson, Publisher, Co-Founder MassDevice (Moderator)
Brian conceived the idea for MassDevice.com in 2007 and launched the publication in March 2009 with Brad Perriello. As publisher, he has spearheaded the growth of the publication from 0 to 75,000 readers each month and led the company to profitability in 2011, just two years after launch.
Full List of confirmed speakers:
- Rick Altinger, CEO, Glooko
- Michelle Axelrod, Principal, Porzio Life Sciences LLC
- Diane Biagianti, VP, Chief Responsibility Officer, Edwards Lifesciences
- Mark Carlson, CMO, St. Jude Medical
- Michael Crompton, Chief Compliance Officer, Revision Optics
- Edward Crowe, Director, Porzio Life Sciences, LLC
- David Dykeman, Shareholder, Co-Chair Global Life Sciences and Medical Technology Group, Greenberg Traurig
- David Gollaher, President, CHI
- Dr. Robert Greenberg, CEO, Second Sight Medical
- Mick Farrell, CEO, ResMed
- Ginger Heyman Pigott, Vice Chairman, Medical Devices, Greenberg Traurig, LLC
- Justin Hibbs, Sr. VP Marketing and Research, aptitude, LLC
- Adam Krauss, Associate General Counsel, Covidien
- Eli Kammerman, VP Business Development, Masimo
- Troy Kirchenbauer, General Manager, aptitude, LLC
- Larry Stofko, EVP, The Innovation Institute
- J. Rick Tache, Shareholder, Greenberg Traurig, LLC
- Richard Yoon, Director of IP Strategy, Medtronic Diabetes
Underwriting for the Big 100 provided by:
Registrations are transferabble but all purchases are final. Please contact us to change your reservation at firstname.lastname@example.org
No, as long as you register prior to the event we will have your name on file and you can check in at the registration desk.